Mombelli G, Coppens L, Thys J P, Klastersky J
Antimicrob Agents Chemother. 1981 Jan;19(1):72-5. doi: 10.1128/AAC.19.1.72.
The penetration of amikacin and tobramycin into bronchial secretions and the resulting anti-Pseudomonas activity were assessed in two groups of tracheostomized or intubated patients with tracheobronchial infection and purulent bronchial secretions. The aminoglycosides were administered as continuous, high-dose intravenous infusions. The mean drug concentrations in serum and bronchial secretions were 12.8 and 2.0 microgram/ml for amikacin and 3.6 and 0.7 microgram/ml for tobramycin. The bronchial secretion/serum ratios varied over a wide range: from 9.6 to 22.8% (average, 14.9%) for amikacin and from 3 to 39.3% (average, 17.5%) for tobramycin. Sustained anti-Pseudomonas activities in bronchial secretions were achieved only in patients with very high aminoglycoside levels in serum. In most patients, however, no anti-Pseudomonas activity could be detected within bronchial secretions despite therapeutic levels of amikacin and tobramycin and adequate bactericidal activities in serum.
在两组患有气管支气管感染且有脓性支气管分泌物的气管切开或插管患者中，评估了阿米卡星和妥布霉素在支气管分泌物中的渗透情况以及由此产生的抗假单胞菌活性。氨基糖苷类药物以持续、高剂量静脉输注的方式给药。阿米卡星在血清和支气管分泌物中的平均药物浓度分别为12.8微克/毫升和2.0微克/毫升，妥布霉素分别为3.6微克/毫升和0.7微克/毫升。支气管分泌物与血清的比例在很宽的范围内变化：阿米卡星为9.6%至22.8%（平均为14.9%），妥布霉素为3%至39.3%（平均为17.5%）。只有血清中氨基糖苷类药物水平非常高的患者，支气管分泌物中才实现了持续的抗假单胞菌活性。然而，在大多数患者中，尽管血清中有治疗水平的阿米卡星和妥布霉素以及足够的杀菌活性，但在支气管分泌物中未检测到抗假单胞菌活性。
